The review of the tumour-suppressive role of GSK-3β in cancer reveals that most of these effects are either not active in pancreatic cancer, such as in the case of p53 regulation, or overcome by other pro-oncogenic effects of GSK-3β, such as in the case of β-catenin, c-Myc, and Snail pathways. The gene discussed is MYC; the disease is pancreatic neoplasm.